Figure 1.
Graphs of veliparib AUC0–9h versus dose (A) and topotecan AUC0−∞ versus veliparib dose (B) following administration of escalating doses of 10 – 400 mg veliparib with 3 mg/m2 topotecan.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.